Stockscreener 앱 받기
22.26
2.05%
0.4588
전일 마감가:
$21.80
열려 있는:
$21.98
하루 거래량:
399.78K
Relative Volume:
0.23
시가총액:
$3.79B
수익:
$1.07B
순이익/손실:
$391.00M
주가수익비율:
9.7268
EPS:
2.2884
순현금흐름:
$6.31M
1주 성능:
+2.24%
1개월 성능:
+7.26%
6개월 성능:
+4.00%
1년 성능:
+55.03%
1일 변동 폭
$21.81
$22.36
1주일 범위
$21.16
$22.37
52주 변동 폭
$14.18
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.25 | 3.72B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
437.01 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.70 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.67 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.23 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-23 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
(ACAD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Assessing Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX Rollout And Upcoming Neurology Data Presentations - Sahm
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting - The National Law Review
ACAD Stock Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $29 - Moomoo
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - MarketBeat
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
ACAD Should I Buy - Intellectia AI
Acadia Pharmaceuticals to Report Q1 2026 Earnings on May 6 - National Today
How Investors Are Reacting To ACADIA Pharmaceuticals (ACAD) Expanding DAYBUE STIX Access for Rett Syndrome - Yahoo Finance
Press Release: Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - Moomoo
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Does ACADIA Pharmaceuticals Inc stock reflect fundamentals2026 Chart Watch & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Breakout Watch: What is the target price for ACADIA Pharmaceuticals Inc stockWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Insider Sells Over $22,000 in Stock - National Today
Neuren Pharmaceuticals advances Rett syndrome treatment with US launch of DAYBUE STIX - BioMelbourne Network
Sectors Review: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
(ACAD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Acadia Pharma EVP Schneyer sells $60k in stock By Investing.com - Investing.com India
Acadia Pharmaceuticals officer sells $22,866 in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock - Investing.com
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Acadia (NASDAQ: ACAD) officer sells shares to cover RSU tax obligations - Stock Titan
Acadia Pharmaceuticals Launches DAYBUE STIX for Rett Syndrome - National Today
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is N - GuruFocus
Acadia Pharmaceuticals (ACAD) Expands Access to Rett Syndrome Tr - GuruFocus
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Bakersfield.com
RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD.MX) Income Statement - Yahoo! Finance Canada
Advantage Alpha Capital Partners LP's ACADIA Pharmaceuticals Inc(ACAD) Holding History - GuruFocus
IPO Launch: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
ACAD PE Ratio & Valuation, Is ACAD Overvalued - Intellectia AI
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII
Insiders At ACADIA Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - 富途牛牛
ACADIA Pharmaceuticals Inc (DR6.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Glioblastoma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic Therapeuti - Barchart
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Layoff Watch: Is ACADIA Pharmaceuticals Inc being accumulated by smart moneyStop Loss & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Update Recap: Can ACADIA Pharmaceuticals Inc continue delivering strong returns - baoquankhu1.vn
Acadia Pharmaceuticals stock drops 3.35% as company gears up for post-acute care conference - Traders Union
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance - simplywall.st
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acadia Pharmaceuticals Inc 주식 (ACAD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Apr 07 '26 |
Sale |
22.20 |
1,030 |
22,866 |
27,865 |
| Owen Adams Catherine | Chief Executive Officer |
Mar 24 '26 |
Option Exercise |
0.00 |
23,509 |
0 |
26,444 |
| Owen Adams Catherine | Chief Executive Officer |
Mar 25 '26 |
Sale |
21.47 |
11,641 |
249,932 |
14,803 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Mar 24 '26 |
Option Exercise |
0.00 |
7,515 |
0 |
15,124 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Mar 25 '26 |
Sale |
21.47 |
3,844 |
82,531 |
11,280 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev |
Mar 25 '26 |
Sale |
21.47 |
3,435 |
73,749 |
3,280 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Mar 26 '26 |
Sale |
21.65 |
1,109 |
24,011 |
26,885 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Mar 25 '26 |
Sale |
21.47 |
833 |
17,885 |
25,852 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Mar 25 '26 |
Sale |
21.47 |
4,177 |
89,680 |
57,299 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Mar 26 '26 |
Sale |
21.65 |
3,208 |
69,456 |
60,269 |
1.15%
0.47%
자본화:
|
볼륨(24시간):